FDA approves trial of neural stem cells to treat Lou Gehrig’s disease
The US Food and Drug Administration (FDA) has granted approval to NeuralStem Inc., a Maryland-based biotherapeutics company, to conduct the first human trial using neural stem cells for treatment of amyotrophic lateral sclerosis (ALS). ALS is a type of motor neuron disease often referred to as 'Lou Gehrig's' and 'Maladie de Charcot'. The late-onset condition, of unknown cause, affects approximately two in 100,000 people, including the UK physicist Stephen Hawking and US rock gui...
Comment
A new era for the HFEA
by Professor Lisa Jardine
When it comes into force on 1 October the new Human Fertilisation and Embryology (HFE) Act will herald the single greatest change to affect the UK fertility sector in nearly two decades, since we - the Human Fertilisation and Embryology Authority (HFEA) - came into being as the UK regulator....
The Human Fertilisation and Embryology Act 2008: Promoting wider access to information about genetic origins?
by Dr Caroline Jones
October sees the enactment of almost the entire Human Fertilisation and Embryology (HFE) Act 2008, including the new disclosure provisions for donor-conceived individuals and gamete/embryo donors. In this commentary I outline the amended disclosure provisions and highlight a number of issues raised by these changes....